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Introduction {#bjs550-sec-0005}
============

Thyroidectomy is the most frequently performed endocrine operation in the world. One of the significant complications is vocal fold paralysis from recurrent laryngeal nerve (RLN) injury, although vocal fold paresis resulting from partial loss of nerve function can also cause postoperative dysphonia. The standard to avoid vocal fold paresis is direct visualization, dissection and protection of the RLN[1](#bjs550-bib-0001){ref-type="ref"}. Using this technique, nerve injury rates have been low, with a temporary RLN palsy rate of 3--8 per cent and a permanent rate of 0·3--3 per cent reported[2](#bjs550-bib-0002){ref-type="ref"}. The reported prevalence of external branch of the superior laryngeal nerve (EBSLN) damage is higher. EBSLN damage produces changes in voice that are heterogeneous and difficult to diagnose. A lesion of the EBSLN impairs motor function of the cricothyroid muscle, affecting the production of high tones, limiting pitch range and voice projection, and leading to phonatory fatigue[3](#bjs550-bib-0003){ref-type="ref"} [4](#bjs550-bib-0004){ref-type="ref"}. The rate of EBSLN injury has been reported to be as high as 28 per cent[5](#bjs550-bib-0005){ref-type="ref"}.

Intraoperative nerve monitoring (IONM) was developed to reduce the incidence of these problems, and in one RCT[6](#bjs550-bib-0006){ref-type="ref"} decreased the rate of temporary RLN palsy from 5·0 to 2·7 per cent (*P* = 0·007). Owing to the low RLN injury rate, most studies are, however, underpowered to detect statistically significant differences and, as a result, the routine use of IONM remains controversial. In response to variations in practice and conflicting data, a consensus statement in 2011 by the International Neural Monitoring Study Group[7](#bjs550-bib-0007){ref-type="ref"} emphasized the importance of standardizing the use of IONM in RLN identification as an adjunct to visualization. When used in a standard fashion during thyroid surgery, nerve monitoring has been shown to improve identification of both the EBSLN and RLN compared with visualization alone[8](#bjs550-bib-0008){ref-type="ref"}. This is especially the case for the EBSLN. An RCT[9](#bjs550-bib-0009){ref-type="ref"} found significantly less severe impairment of the voice handicap score in monitored patients than in those who had direct visualization alone (2·6 *versus* 11·2 per cent respectively; *P* = 0·021).

In addition, reports suggest that damage to the strap muscles can lead to voice impairment[10](#bjs550-bib-0010){ref-type="ref"}, although no causal relation between voice changes and transection of the strap muscles has been established.

The aim of the present study was to determine the prevalence and nature of voice dysfunction following thyroid surgery with IONM and routine strap muscle division.

Methods {#bjs550-sec-0006}
=======

A cohort of consecutive patients undergoing thyroidectomy who completed informed consent and preoperative and postoperative vocal function assessment were included in the study. Operations were performed by the same single surgeon. Data were held in a specific database approved by the Northern Sydney Area ethics committee. Videostroboscopy and voice assessment were performed on all patients before surgery and at 1 and 3 months after surgery by an independent laryngologist and speech--language therapist. Demographics, type of operation, pathology, visualization of EBSLN and RLN, findings at IONM, EBSLN subtype classification[11](#bjs550-bib-0011){ref-type="ref"} and complications were recorded. The Voice Handicap Index (VHI) 10 questionnaire result was used as the primary outcome measure. Secondary outcome measurements were based on objective acoustic analysis of recorded voice samples. The preoperative voice outcome assessment functioned as the control for postoperative tests.

Voice Handicap Index‐10 {#bjs550-sec-0007}
-----------------------

The VHI‐10 is a validated short version of the 30‐item VHI questionnaire consisting of the ten most robust items[12](#bjs550-bib-0012){ref-type="ref"}. This questionnaire is used to assess the patient\'s voice‐related quality of life before surgery and 1 and 3 months after surgery.

Acoustic analysis {#bjs550-sec-0008}
-----------------

Standardized voice recordings were taken in a quiet room with background noise minimized to less than 50 dB and captured with a Quad‐Capture USB sound card (Roland Corporation, Nakagawa, Japan) and an AKG C540 head‐mounted cardioid microphone (Harman International, Stamford, Connecticut, USA), positioned 5 cm from the edge of the lips. The recordings were captured with WavePad audio software 2015 (NCH Software, Greenwood Village, Colorado, USA) at 44 100 Hz, 16‐bit sample rate, and saved as a .wav file. The text and sentences were standardized (*Appendix* [S1](#bjs550-supitem-0001){ref-type="supplementary-material"}, supporting information).

Participants were asked to read the Rainbow Passage as a connected speech sample, to produce an /a/ vowel for as long as they could and produce a pitch glide task on /i/. The recordings were analysed for fundamental frequency of connected speech (*f*0), harmonic to noise ratio on a 4‐s segment of prolonged /a/ vowel (HNR), and minimum and maximum frequency (on the pitch glide task) using the Praat speech tool version 5.3.75[13](#bjs550-bib-0013){ref-type="ref"}. The speech tool was used for the cepstral peak prominence (CPP) and smoothed cepstral peak prominence (CPPS) analyses, performed on the connected speech sample[14](#bjs550-bib-0014){ref-type="ref"}. Maximum phonation time (MPT) was taken from the longest /a/ vowel produced in three attempts and was measured in seconds in WavePad once the recording was complete.

Surgical protocol {#bjs550-sec-0009}
-----------------

Thyroidectomy was performed in a standard fashion under general anaesthesia and cervical block; intubation was with the TriVantage® EMG endotracheal tube (Medtronic, Jacksonville, Florida, USA). The patient was positioned supine with a shoulder roll providing neck extension. A cervical incision in a skin crease was performed and the strap muscles were routinely transected, preserving innervation by the ansa cervicalis, and resuturing with a 3/0 polyglactin suture (Vicryl™; Ethicon, Somerville, New Jersey, USA) at the conclusion of the procedure. The LigaSure™ (Medtronic) thermal sealing system was used for dissection and ligation. IONM was performed with the NIM® 3.0 system (Medtronic). Before dissection of the thyroid, the system was checked by vagal response.

Visual identification of the EBSLN was carried out as reported previously[15](#bjs550-bib-0015){ref-type="ref"} and confirmed using the nerve monitor. A positive result was recorded when strong and simultaneous contraction of the pars recta and pars oblique components of the cricothyroid muscle was observed. The RLN was also identified and dissected over the course of the nerve, with monitoring again used to confirm nerve function. In all patients with loss of signal, contralateral stimulation of the vagus nerve was performed to exclude equipment failure and palpation for a cricopharyngeal twitch on ipsilateral stimulation of the RLN and vagus nerve. Failure to confirm the integrity of the nerve after dissection was recorded.

Statistical analysis {#bjs550-sec-0010}
--------------------

Statistical analysis was performed using SPSS® version 24.0 (IBM, Armonk, New York, USA) data analysis software. Baseline characteristics were described as mean(s.d.) or median (range) values for continuous variables, and as counts with percentages for categorical variables. For continuous variables, differences between groups per time point were calculated with ANOVA for independent samples. The Kruskal--Wallis test was used to compare medians between all groups per time point. The significance of change over time per outcome for continuous variables was determined with the generalized linear mixed model for paired data. VHI‐10 outcomes are ordinal and thus *P* values were calculated using a generalized estimating equation model for repeated measures. Outcomes with incomplete data over time were excluded from analysis. *P* \< 0·050 was considered significant.

Results {#bjs550-sec-0011}
=======

Of 102 patients, 70 (69 per cent) underwent total thyroidectomy and 32 (31 per cent) had a hemithyroidectomy, resulting in a total of 172 EBSLNs and RLNs at risk (*Tables* [1](#bjs550-tbl-0001){ref-type="table-wrap"} and [2](#bjs550-tbl-0002){ref-type="table-wrap"}). All nerves at risk were identified during surgery, but 23·3 per cent of EBSLNs and 0·6 per cent of RLNs required the assistance of IONM as well as visualization. Nerve integrity was confirmed during surgery for 98·8 per cent of EBSLNs and 98·3 per cent of RLNs. There were no significant differences between median preoperative and postoperative VHI‐10 scores, or in objective outcome measures over the three different time points for all patients combined (*Table* [3](#bjs550-tbl-0003){ref-type="table-wrap"}).

###### 

Baseline characteristics of patients and nerves at risk

                                                       No. of patients (*n* = 102)
  --------------------------------------------------- -----------------------------
  Age (years)[\*](#bjs550-note-0003){ref-type="fn"}           54·5 (21--84)
  Sex ratio (F : M)                                              85 : 17
  Type of surgery                                     
  Total thyroidectomy                                           70 (68·6)
  Hemithyroidectomy                                             32 (31·4)
  Lymph node dissection                                         15 (14·7)
  Indication for surgery                              
  Risk of malignancy                                            43 (42·2)
  Goitre                                                        43 (42·2)
  Thyrotoxicosis                                                14 (13·7)
  Other                                                          2 (2·0)
  Histopathology                                      
  Goitre                                                        54 (52·9)
  Thyroiditis                                                    4 (3·9)
  Other benign                                                  22 (21·6)
  Carcinoma                                                     22 (21·6)

Values in parentheses are percentages unless indicated otherwise;

values are median (range).

###### 

Baseline characteristics of nerves at risk

                                                                No. of nerves at risk             
  ------------------------------------------------------------- ----------------------- --------- -----------
  EBSLN                                                                                           
  Cernea classification[11](#bjs550-bib-0011){ref-type="ref"}                                     
  Type 1                                                        23 (28)                 44 (49)    67 (39·0)
  Type 2a                                                       42 (51)                 27 (30)    69 (40·1)
  Type 2b                                                       10 (12)                 8 (9)      18 (10·5)
  Missing                                                       7 (9)                   11 (12)    18 (10·5)
  IONM‐assisted identification                                  20 (24)                 20 (22)    40 (23·3)
  Loss of signal                                                1 (1)                   1 (1)       2 (1·2)
  RLN                                                                                             
  IONM‐assisted identification                                  0 (0)                   1 (1)       1 (0·6)
  Not identified                                                0 (0)                   1 (1)       1 (0·6)
  Missing                                                       2 (2)                   2 (2)       4 (2·3)
  Loss of signal                                                3 (4)                   0 (0)       3 (1·7)

Values in parentheses are percentages. EBLSN, external branch of the superior laryngeal nerve; IONM, intraoperative nerve monitoring; RLN, recurrent laryngeal nerve.

###### 

Results of the objective patient‐reported outcome according to the Voice Handicap Index‐10 over time

                                         Voice Handicap Index‐10 score[\*](#bjs550-note-0005){ref-type="fn"}                                      
  ----------------------- ------------- --------------------------------------------------------------------- ------------- ------- ------------- -------
  Total thyroidectomy                                                   0·015                                                0·464                 0·221
  No                      5·5 (0--29)                                                                         3·0 (0--29)           2·0 (0--19)   
  Yes                     1·0 (0--21)                                                                         2·0 (0--34)           1·5 (0--23)   
  Lymph node dissection                                                 0·022                                                0·650                 0·515
  No                      2·0 (0--29)                                                                         2·0 (0--34)           2·0 (0--23)   
  Yes                     0·0 (0--5)                                                                          3·0 (0--17)           1·5 (0--11)   
  Loss of signal                                                        0·456                                                0·538                 0·888
  No                      1·0 (0--29)                                                                         2·0 (0--29)           2·0 (0--23)   
  Yes                     2·0 (0--21)                                                                         2·0 (0--34)           1·0 (0--11)   
  Cancer                                                                0·175                                                0·805                 0·898
  No                      2·0 (0--29)                                                                         2·0 (0--34)           2·0 (0--23)   
  Yes                     0·5 (0--13)                                                                         4·0 (0--17)           2·0 (0--13)   

Values are median (range).

Kruskal--Wallis test.

Voice Handicap Index‐10 {#bjs550-sec-0012}
-----------------------

Type of thyroidectomy did not influence objective voice outcomes (*Table* [3](#bjs550-tbl-0003){ref-type="table-wrap"}). The preoperative VHI‐10 score was significantly higher in patients who had a hemithyroidectomy or no lymph node dissection. The VHI‐10 score did not change after 1 and 3 months with respect to the different predictors (*Table* [3](#bjs550-tbl-0003){ref-type="table-wrap"}). Intraoperative loss of signal in either nerve seemed to be a significant predictor of postoperative change in the VHI‐10 score, although median VHI‐10 changes in patients with and without intraoperative loss of signal showed no clinically relevant differences (*Table* [3](#bjs550-tbl-0003){ref-type="table-wrap"}).

Acoustic analysis {#bjs550-sec-0013}
-----------------

Patients had a significantly lower *f*0 (highest) value at 1 month after surgery compared with the preoperative value (461·3 *versus* 515·2 Hz respectively; *P* = 0·005) (*Table* [4](#bjs550-tbl-0004){ref-type="table-wrap"}). After 3 months there was complete recovery. Overall, all objective voice outcomes showed no changes 3 months after surgery compared with preoperative values (*Table* [4](#bjs550-tbl-0004){ref-type="table-wrap"}). Patients who underwent total thyroidectomy had significantly lower *f*0 (highest) values before surgery and at 1 month compared with those having a hemithyroidectomy. This difference tended to disappear at 3 months (*Table* [5](#bjs550-tbl-0005){ref-type="table-wrap"}). There were no differences in acoustic outcomes between patients who underwent lymph node dissection and those who did not (*Table* [6](#bjs550-tbl-0006){ref-type="table-wrap"}). MPT was significantly reduced 1 month after surgery in patients who had loss of signal during surgery, but it returned to the preoperative baseline after 3 months (*Table* [7](#bjs550-tbl-0007){ref-type="table-wrap"}). CPP and CPPS were significantly lower after 3 months in patients who had loss of signal during operation (*Table* [7](#bjs550-tbl-0007){ref-type="table-wrap"}). Histopathological findings were stratified by benign or malignant outcome. Malignant outcome included all cancer subtypes and sizes, with a mean of 22 (range 4--80) mm. Histopathological findings did not influence objective voice outcome measures (*Table* [8](#bjs550-tbl-0008){ref-type="table-wrap"}).

###### 

Overall changes in objective outcome measurements over time

                                                                               After surgery[\*](#bjs550-note-0007){ref-type="fn"}                                                     
  --------------------- ---- ------------------------------------------------- ----------------------------------------------------- ------------------------------------------------- ---------------------------------------------
  MPT (s)               99   17·1(7·1)                                         15·2(6·7)                                             13·4(7·2)                                         0·854  
  *f*0 (Hz)             85   190·4(51·6)                                       194·6(49·8)                                           194·4(43·4)                                       0·418  
  *f*0 (lowest) (Hz)    82   128·9(33·1)                                       125·8(38·6)                                           128·3(31·1)                                       0·782  
  *f*0 (highest) (Hz)   82   515·2(218·9)                                      461·3(200·1)                                          505·5(202·2)                                      0·654  
  HNR (Hz)              83   20·4(3·7)                                         20·3(4·2)                                             20·5(3·8)                                         0·774  
  CPP (dB)              80   12·3(0·8)                                         12·2(0·8)                                             12·3(0·8)                                         0·957  
  CPPS (dB)             79   4·2(0·5)                                          4·1(0·5)                                              4·2(0·5)                                          0·307  
  VHI‐10                99   2·0 (0--6)[†](#bjs550-note-0010){ref-type="fn"}   2·0 (0--8)[†](#bjs550-note-0010){ref-type="fn"}       2·0 (0--6)[†](#bjs550-note-0010){ref-type="fn"}   0·326[§](#bjs550-note-0009){ref-type="fn"} 

Values are mean(s.d.) unless indicated otherwise;

values are median (i.q.r.). MPT, maximum phonation time; *f*0, fundamental frequency; HNR, harmonic to noise ratio; CPP, cepstral peak prominence; CPPS, smoothed cepstral peak prominence; VHI, Voice Handicap Index.

Generalized linear mixed model, except

generalized estimating equation.

###### 

Objective voice outcome measures for each time point, stratified for type of thyroidectomy (hemithyroidectomy versus total thyroidectomy)

                                               After surgery                          
  --------------------- -------------- ------- --------------- ------- -------------- -------
  MPT (s)                               0·264                   0·228                  0·183
  No                    18·3(7·3)              16·5(6·2)               15·0(6·6)      
  Yes                   16·6(7·0)              14·8(7·0)               12·9(7·5)      
  *f*0 (Hz)                             0·274                   0·865                  0·312
  No                    177·5(66·1)            196·0(57·0)             187·6(44·6)    
  Yes                   190·5(49·6)            194·1(48·8)             197·4(41·7)    
  *f*0 (lowest) (Hz)                    0·759                   0·853                  0·407
  No                    128·5(35·7)            125·4(46·4)             124·1(34·2)    
  Yes                   126·2(33·7)            126·9(33·6)             130·0(30·1)    
  *f*0 (highest) (Hz)                   0·040                   0·026                  0·055
  No                    572·8(250·0)           524·1(225·8)            567·0(213·1)   
  Yes                   478·2(185·9)           431·7(193·0)            479·7(190·8)   
  HNR (Hz)                              0·513                   0·157                  0·314
  No                    20·6(2·9)              19·5(3·9)               20·0(4·1)      
  Yes                   20·0(4·7)              20·8(4·1)               20·1(3·8)      
  CPP (dB)                              0·311                   0·797                  0·506
  No                    12·1(0·8)              12·2(0·8)               12·3(0·7)      
  Yes                   12·3(0·8)              12·2(0·8)               12·2(0·8)      
  CPPS (dB)                             0·222                   0·510                  0·722
  No                    4·1(0·5)               4·1(0·6)                4·2(0·6)       
  Yes                   4·2(0·6)               4·2(0·6)                4·2(0·6)       

Values are mean(s.d.). MPT, maximum phonation time; *f*0, fundamental frequency; HNR, harmonic to noise ratio; CPP, cepstral peak prominence; CPPS, smoothed cepstral peak prominence.

ANOVA.

###### 

Objective voice outcome measures for each time point, stratified for lymph node dissection

                                               After surgery[\*](#bjs550-note-0013){ref-type="fn"}                          
  --------------------- -------------- ------- ----------------------------------------------------- ------- -------------- -------
  MPT (s)                               0·547                                                         0·212                  0·119
  No                    16·9(6·3)              15·0(6·3)                                                     13·1(6·9)      
  Yes                   18·2(11·3)             17·4(9·4)                                                     16·4(8·7)      
  *f*0 (Hz)                             0·836                                                         0·350                  0·957
  No                    186·8(53·6)            192·8(51·9)                                                   194·0(43·2)    
  Yes                   183·5(67·4)            207·2(47·3)                                                   194·7(41·6)    
  *f*0 (lowest) (Hz)                    0·333                                                         0·619                  0·375
  No                    128·2(32·3)            125·7(38·3)                                                   126·8(31·6)    
  Yes                   118·3(45·8)            131·6(37·6)                                                   135·9(31·7)    
  *f*0 (highest) (Hz)                   0·014                                                         0·990                  0·490
  No                    527·5(211·7)           462·4(201·5)                                                  515·5(212·0)   
  Yes                   374·0(154·0)           463·1(123·4)                                                  470·2(106·5)   
  HNR (Hz)                              0·050                                                         0·851                  0·637
  No                    20·5(4·1)              20·3(4·1)                                                     20·6(3·9)      
  Yes                   18·1(4·1)              20·5(3·9)                                                     20·1(3·1)      
  CPP (dB)                              0·778                                                         0·514                  0·771
  No                    12·2(0·8)              12·2(0·8)                                                     12·3(0·8)      
  Yes                   12·3(0·9)              12·1(1·2)                                                     12·3(1·0)      
  CPPS (dB)                             0·930                                                         0·711                  0·987
  No                    4·2(0·6)               4·2(0·5)                                                      4·2(0·6)       
  Yes                   4·2(0·6)               4·1(0·6)                                                      4·2(0·6)       

Values are mean(s.d.). MPT, maximum phonation time; *f*0, fundamental frequency; HNR, harmonic to noise ratio; CPP, cepstral peak prominence; CPPS, smoothed cepstral peak prominence.

ANOVA.

###### 

Objective voice outcome measures for each time point, stratified for intraoperative loss of signal of any nerve

                                               After surgery[\*](#bjs550-note-0015){ref-type="fn"}                          
  --------------------- -------------- ------- ----------------------------------------------------- ------- -------------- -------
  MPT (s)                               0·671                                                        0·006                   0·887
  No                    17·2(7·3)              15·7(6·6)                                                     13·6(7·4)      
  Yes                   15·8(2·6)              7·2(6·7)                                                      13·1(2·1)      
  *f*0 (Hz)                             0·894                                                        0·570                   0·694
  No                    186·2(56·5)            194·2(51·8)                                                   194·5(43·6)    
  Yes                   189·6(27·5)            211·4(33·1)                                                   186·7(25·9)    
  *f*0 (lowest) (Hz)                    0·440                                                        0·948                   0·472
  No                    126·3(34·6)            126·5(38·7)                                                   128·6(31·3)    
  Yes                   138·5(26·4)            125·0(5·9)                                                    118·1(37·9)    
  *f*0 (highest) (Hz)                   0·995                                                        0·253                   0·395
  No                    507·1(215·2)           466·6(194·6)                                                  514·4(204·9)   
  Yes                   507·7(116·0)           336·7(49·8)                                                   434·7(136·2)   
  HNR (Hz)                              0·002                                                        0·900                   0·563
  No                    20·5(3·7)              20·3(4·0)                                                     20·5(3·8)      
  Yes                   14·5(8·7)              20·6(6·2)                                                     21·5(2·1)      
  CPP (dB)                              0·172                                                        0·110                   0·039
  No                    12·3(0·8)              12·2(0·8)                                                     12·3(0·8)      
  Yes                   11·8(0·8)              11·4(0·8)                                                     11·6(1·0)      
  CPPS (dB)                             0·173                                                        0·448                   0·039
  No                    4·2(0·6)               4·2(0·6)                                                      4·2(0·5)       
  Yes                   3·9(0·6)               3·9(0·3)                                                      3·7(1·0)       

Values are mean(s.d.). MPT, maximum phonation time; *f*0, fundamental frequency; HNR, harmonic to noise ratio; CPP, cepstral peak prominence; CPPS, smoothed cepstral peak prominence.

ANOVA.

###### 

Objective voice outcome measures for each time point, stratified for histopathology outcome

                                               After surgery[\*](#bjs550-note-0016){ref-type="fn"}                          
  --------------------- -------------- ------- ----------------------------------------------------- ------- -------------- -------
  MPT (s)                               0·234                                                         0·197                  0·178
  Benign                16·7(6·1)              14·9(6·4)                                                     13·0(6·8)      
  Malignant             18·8(10·1)             17·0(8·0)                                                     15·4(8·4)      
  *f*0 (Hz)                             0·715                                                         0·733                  0·631
  Benign                187·4(54·4)            193·8(51·9)                                                   195·2(43·9)    
  Malignant             182·5(59·9)            198·1(50·4)                                                   189·9(38·8)    
  *f*0 (lowest) (Hz)                    0·096                                                         0·328                  0·738
  Benign                129·9(32·2)            128·4(36·2)                                                   128·6(31·8)    
  Malignant             115·9(39·9)            119·0(44·8)                                                   125·8(31·1)    
  *f*0 (highest) (Hz)                   0·067                                                         0·944                  0·842
  Benign                527·5(205·8)           461·8(190·9)                                                  512·0(217·6)   
  Malignant             432·5(217·7)           465·2(209·3)                                                  501·3(129·2)   
  HNR (Hz)                              0·243                                                         0·614                  0·283
  Benign                20·5(4·1)              20·4(4·1)                                                     20·8(3·8)      
  Malignant             19·2(4·4)              19·9(4·1)                                                     19·8(3·7)      
  CPP (dB)                              0·574                                                         0·587                  0·968
  Benign                12·3(0·8)              12·2(0·8)                                                     12·3(0·8)      
  Malignant             12·2(0·8)              12·1(0·9)                                                     12·3(0·8)      
  CPPS (dB)                             0·115                                                         0·306                  0·428
  Benign                4·3(0·6)               4·2(0·6)                                                      4·2(0·6)       
  Malignant             4·0(0·6)               4·1(0·6)                                                      4·2(0·6)       

Values are mean(s.d.). MPT, maximum phonation time; *f*0, fundamental frequency; HNR, harmonic to noise ratio; CPP, cepstral peak prominence; CPPS, smoothed cepstral peak prominence.

ANOVA.

Discussion {#bjs550-sec-0014}
==========

IONM during thyroid surgery is widely used, frequently employing the standards set by the International Neural Monitoring Study Group[7](#bjs550-bib-0007){ref-type="ref"} [16](#bjs550-bib-0016){ref-type="ref"}. The present study has shown that IONM contributed to reliable identification of the RLN and EBSLN in 0·6 and 23·3 per cent of nerves respectively. The impact of reliable identification of the RLN and EBSLN with IONM correlated with clinical preservation of voice outcome after thyroid surgery.

In this cohort, transection of the strap muscles while preserving the ansa cervicalis was routine. The results showed that this element of the surgery did not impair voice outcome. Overall, there were no clinically relevant changes in voice‐related quality of life in the study group regarding patient‐reported outcomes, with a stable median VHI‐10 score of 2·0 before and after surgery, whereas the normal score is less than 7. Objective measurements performed by an independent laryngologist and speech--language therapist also showed no clinically relevant changes in all six variables after surgery.

The VHI‐10 score represents the patient\'s experience of voice changes. Of all clinical factors tested for their influence on VHI‐10 outcomes, none resulted in a prolonged reduction of voice outcome. In contrast to a previous report[17](#bjs550-bib-0017){ref-type="ref"} concluding that strap muscle division impairs voice outcome, the present results show that meticulous identification of all nerves is the main contributor to maintaining vocal outcome.

Subgroup analyses assessing the influence of lymph node dissection, total thyroidectomy, histopathological outcome and intraoperative loss of signal found no clinically significant changes in voice outcome, despite some reaching statistical significance. None of these, however, appeared to reflect clinically significant or long‐term impairment of vocal function. Nonetheless, CPP and CPPS were significantly lower after 3 months in patients who had loss of signal during operation. This was not the case at 1 month and could not be explained by a mutual reduction after 1 month in combination with lack of recovery for patients with loss of signal. This may be a late result of intraoperative loss of signal.

The main limitation of this study was the lack of a control group for direct comparison of the effect of nerve monitoring on voice outcome. The studied cohort was also small. The rare nature of nerve damage means that very large numbers of patients would be needed to generate sufficient power for the study. Cricothyroid electromyography was not performed in this study, although the rate of EBSLN injury was assessed by identification of cricothyroid twitch and indirectly during follow‐up by videostroboscopy.

Thyroidectomy with IONM confirmation of postdissection RLN and EBSLN function and routine division of strap muscles resulted in no clinically significant voice change as measured in an independent laryngology clinic.

Disclosure {#bjs550-sec-0015}
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###### 

**Appendix S1** Standardized voice recording/assessment protocol

###### 

Click here for additional data file.
